Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry.
Latest Information Update: 13 Dec 2022
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms EVHALAVEN
- Sponsors Eisai Co Ltd
- 01 Nov 2022 Results published in the European Journal of Cancer Care
- 11 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 According to an Eisai media release, data from this study will be presented at the 18th Biennial Congress of European Cancer Congress (ECC).